These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 17932598

  • 21. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
    Wang JR, Zhao HZ, Chang LJ, Xu X, Gao Y, Li M, Kong QY, Wang MM, Zhao CF.
    Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
    [Abstract] [Full Text] [Related]

  • 22. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 23. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 24. [Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin].
    Mori M.
    Nihon Rinsho; 2008 Feb; 66(2):349-54. PubMed ID: 18260334
    [Abstract] [Full Text] [Related]

  • 25. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
    Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A.
    Circulation; 2006 Jun 06; 113(22):2606-12. PubMed ID: 16735679
    [Abstract] [Full Text] [Related]

  • 26. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 06; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 27. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 06; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 28. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
    Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2005 Nov 06; 32(11):2233-8. PubMed ID: 16265708
    [Abstract] [Full Text] [Related]

  • 29. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
    Arch Dis Child; 2011 Nov 06; 96(11):1088-90. PubMed ID: 20551193
    [Abstract] [Full Text] [Related]

  • 30. [Clinical features of recurrent Kawasaki disease in 20 children].
    Zou LX, Gong FQ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct 06; 10(5):617-9. PubMed ID: 18947484
    [Abstract] [Full Text] [Related]

  • 31. Kawasaki disease with lymphadenopathy and fever as sole initial manifestations.
    Kubota M, Usami I, Yamakawa M, Tomita Y, Haruta T.
    J Paediatr Child Health; 2008 Jun 06; 44(6):359-62. PubMed ID: 18476929
    [Abstract] [Full Text] [Related]

  • 32. Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease.
    Furuno K, Takada H, Yamamoto K, Ikeda K, Ohno T, Khajoee V, Mizuno Y, Hara T.
    J Pediatr; 2007 Aug 06; 151(2):155-60, 160.e1. PubMed ID: 17643768
    [Abstract] [Full Text] [Related]

  • 33. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
    Senzaki H, Kobayashi T, Nagasaka H, Nakano H, Kyo S, Yokote Y, Sasakid N.
    Pediatr Res; 2003 Jun 06; 53(6):983-8. PubMed ID: 12621103
    [Abstract] [Full Text] [Related]

  • 34. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
    Zhang H, Cai J, Zhang R, Shuai S, Tang M, Ju R, Hu Y, Zuo T, Yang Y.
    J Int Med Res; 2024 May 06; 52(5):3000605241252115. PubMed ID: 38713460
    [Abstract] [Full Text] [Related]

  • 35. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
    Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
    Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
    [Abstract] [Full Text] [Related]

  • 36. Outcomes of Kawasaki Disease: A Single-Center Experience.
    Uysal F, Bostan OM, Celebi S, Uysal B, Hamitoglu S, Cil E.
    Clin Pediatr (Phila); 2015 Jun 21; 54(6):579-84. PubMed ID: 25475592
    [Abstract] [Full Text] [Related]

  • 37. Fulfillment of diagnostic criteria in Kawasaki disease.
    Stapp J, Marshall GS.
    South Med J; 2000 Jan 21; 93(1):44-7. PubMed ID: 10653064
    [Abstract] [Full Text] [Related]

  • 38. Prediction of coronary artery lesions based on C-reactive protein levels in children with Kawasaki Disease: a retrospective cohort study.
    Shuai S, Zhang H, Zhang R, Tang M, Luo E, Yang Y, Gao Y, Yue S, Liang H, Cai J.
    J Pediatr (Rio J); 2023 Jan 21; 99(4):406-412. PubMed ID: 36977496
    [Abstract] [Full Text] [Related]

  • 39. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan 21; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 40. Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000).
    Lee KY, Han JW, Lee HS, Hong JH, Hahn SH, Lee JS, Whang KT.
    Pediatr Infect Dis J; 2004 Jan 21; 23(1):52-5. PubMed ID: 14743047
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.